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Abstract
Background: Kaiso has been identified as a new member of the POZ-zinc finger family of transcription
factors that are implicated in development and cancer. Although controversy still exists, Kaiso is supposed
to be involved in human cancer. However, there is limited information regarding the clinical significance of
cytoplasmic/nuclear Kaiso in human lung cancer.
Methods: In this study, immunohistochemical studies were performed on 20 cases of normal lung tissues
and 294 cases of non-small cell lung cancer (NSCLC), including 50 cases of paired lymph node metastases
and 88 cases with complete follow-up records. Three lung cancer cell lines showing primarily nuclear
localization of Kaiso were selected to examine whether roles of Kaiso in cytoplasm and in nucleus are
identical. Nuclear Kaiso was down-regulated by shRNA technology or addition a specific Kaiso antibody
in these cell lines. The proliferative and invasive abilities were evaluated by MTT and Matrigel invasive
assay, transcription of Kaiso's target gene matrilysin was detected by RT-PCR.
Results:  Kaiso was primarily expressed in the cytoplasm of lung cancer tissues. Overall positive
cytoplasmic expression rate was 63.61% (187/294). The positive cytoplasmic expression of Kaiso was
higher in advanced TNM stages (III+IV) of NSCLC, compared to lower stages (I+II) (p = 0.019). A
correlation between cytoplasmic Kaiso expression and lymph node metastasis was found (p = 0.003). In
50 paired cases, cytoplasmic expression of Kaiso was 78.0% (41/50) in primary sites and 90.0% (45/50) in
lymph node metastases (p = 0.001). The lung cancer-related 5-year survival rate was significantly lower in
patients who were cytoplasmic Kaiso-positive (22.22%), compared to those with cytoplasmic Kaiso-
negative tumors (64.00%) (p = 0.005). Nuclear Kaiso staining was seen in occasional cases with only a
5.10% (15/294) positive rate and was not associated with any clinicopathological features of NSCLC.
Furthermore, after the down-regulation of the nuclear expresses Kaiso in vitro, both proliferative and
invasive abilities of three cancer cell lines were significantly enhanced, along with the up-regulation of Kaiso
target gene, matrilysin.
Conclusion: Our data suggest cytoplasmic Kaiso expression is associated with poor prognosis of NSCLC
and various subcellular localizations of Kaiso may play differential biological roles in NSCLC.
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Background
The transcriptional repressor Kaiso belongs to the BTB/
POZ (Broad-Complex, Tramtrack and Bric-a-brac/Pox
virus, and Zinc finger) family[1,2]. This protein contains
an amino-terminal, protein-protein interaction BTB/POZ
domain and a carboxyl-terminal DNA-binding C2H2 zinc
finger domain[2]. To date, Kaiso appears to be the only
known POZ-ZF transcription factor that possesses bi-
modal DNA-binding activity. The candidate Kaiso target
genes identified thus far, such as matrilysin, c-myc, and cyc-
lin D1, seem to be regulated via its zinc finger
domain[3,4].
However, the role of Kaiso still needs to be defined in
tumorigenesis. Considering that some cancer-associated
canonical and noncanonical Wnt target gene, such as mat-
rilysin and Wnt11[3,5], are repressed by Kaiso, it seems
that this protein might function as a tumor suppressor.
Conversely, data obtained from Kaiso-null mice strongly
conflicts with this notion[6]. When Kaiso-deficient mice
were cross-bred with the well-characterized, tumor-sus-
ceptible ApcMin/+ mice, the progeny showed resistance to
intestinal tumorigenesis. Furthermore, a recent study car-
ried out in colon cancer cell lines suggests that Kaiso is a
methylation-dependent "opportunistic" oncogene, which
represses the tumor suppressor gene CDKN2A and pro-
vides a survival advantage to colon cancer cells[7].
Although controversy still exists, there is no question
regarding Kaiso's involvement in human cancer.
To date, little clinicopathological report has referred to the
relationship between Kaiso expression and the malignant
characteristics of human tumors, including lung cancer.
Soubry A. et al. initially attempt to explore the expression
pattern of Kaiso in human tissues using immunohisto-
chemistry[8]. Interestingly, they found that, in contrast to
the nuclear localization of cultured cells (such as MDCK,
NIH3T3, HT29, and SW48), this transcription factor pre-
dominantly localized to the cytosol in both cancerous and
noncancerous human tissues. They also showed that the
subcellular localization of Kaiso was dynamic, rather than
static, and this phenomenon may contribute to an unex-
pected influence of the microenvironment. However, fur-
ther studies are still needed on many topics, including
whether this transcription factor exerts a function in the
cytoplasm, whether Kaiso is expressed in lung cancer, and
the correlation between the subcellular localization of
Kaiso and tumor grade and/or prognosis. These issues
prompted us to determine the expression profile of Kaiso
and to clarify the relationship between Kaiso expression
and tumor clinicopathological features in lung cancers,
using a large specimen size.
In the current study, we examined the expression of Kaiso
in 294 cases of non-small cell lung cancer (NSCLC) and
analyzed the correlation between the expression of Kaiso
and clinicopathological factors. Meanwhile, Kaiso expres-
sion in 50 cases of nodal metastases was probed to inves-
tigate differences between primary lung cancers and
paired lymph node metastases. In order to obtain prog-
nostic data more quickly, immunohistochemistry was
performed on partial lung cancer paraffin embedded tis-
sues from five years ago to determine the expression of
Kaiso. The effect of Kaiso on prognosis of the patients with
lung cancer was analyzed by inspecting follow-up data. In
addition, we ablated Kaiso, which is principally localized
in the nuclei of cells, in three lung cancer cell lines to
investigate alterations in both matrilysin transcription and
in the cells, proliferative and invasive abilities, to provide
insight into the role of Kaiso in the progression of lung
cancers.
Methods
Tissue samples
Tumor specimens from 294 patients with NSCLC were
obtained between 1998 and 2005 following surgical
resection at the First Affiliated Hospital of China Medical
University. 20 cases (included in the 294 cases) of tumor
and paired non-tumor portion (with >5 cm distance from
the primary tumor's edge) of the same case were quickly
frozen in liquid nitrogen and maintained at -70°C for
protein analysis. Among the 294 cases, the lymph node
metastases of 50 patients were available. None of the
patients had received radiotherapy, chemotherapy, or
immunotherapy prior to tumor excision. Of the patients,
165 are male and 129 are female, creating a 1.87:1 ratio of
male to female. Patients' ages at the time of surgery ranged
from 35 to 81, with an average age of 57.24 years old. The
tumors were classified according to the TNM stage revised
by the International Union Against Cancer (UICC) in
2002[9]. All specimens were re-evaluated for diagnosis
following the criteria for classification of lung cancer by
the World Health Organization (WHO) [10], and 133
squamous cell carcinomas and 146 adenocarcinomas
were confirmed. A total of 50 samples (21 squamous cell
carcinoma, 23 adenocarcinoma, and 6 large cell carci-
noma) with autologous lymph node metastases were used
as paired samples to perform immunohistochemical anal-
ysis. In addition, immunohistochemistry was completed
on 88 cases of primary NSCLC paraffin specimens, excised
from February 1998 to October 2007, which had com-
plete follow-up records. This study was conducted under
the regulations of the Institutional Review Board of China
Medical University. Informed consent was obtained from
all enrolled patients prior to surgery.
Immunohistochemical staining and evaluation
As described previously [11-14], formalin-fixed, paraffin-
embedded specimens were cut into 4 μm-thick sequential
sections. After dewaxing in xylene and rehydrating step-BMC Cancer 2009, 9:178 http://www.biomedcentral.com/1471-2407/9/178
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wise in ethanol, sections were boiled in citrate buffer (pH
6.0) for 105 seconds within an autoclave. Endogenous
peroxidase activity and non-specific binding were blocked
with 3% H2O2 and non-immune sera, respectively. Sec-
tions were then incubated with primary antibodies over-
night at 4°C. Specifically, mouse anti-human Kaiso
monoclonal antibody (clone 6F, Upstate, Lake Placid, NY,
USA) and goat anti-human Kaiso polyclonal antibody (C-
18, Santa Cruz Biotechnology, Inc. CA, USA) were used at
concentration of 4 μg/ml. The following day, the staining
was followed by incubation with biotinylated secondary
antibodies (Maixin Biotechnology, Fuzhou, Fujian,
China). The peroxidase reaction was developed with 3, 3'-
diaminobenzidine tetrahydrochloride (MaiXin Biotech-
nology). Counterstaining was done lightly with hematox-
ylin, and the sections were dehydrated in alcohol before
mounting. For the negative control, phosphate-buffered
saline (PBS) was used in place of the primary antibodies.
All of the stained sections were assessed by three observers
(S.D.D., Y.W. and E.H.W) who had no knowledge of the
patients' clinical status. Cases with discrepancies were
jointly re-evaluated by the investigators, and a consensus
was obtained. The sections were evaluated at low magni-
fication (×100) to identify areas where Kaiso was evenly
stained. We counted 400 tumor cells and calculated the
percentage of positively staining cells. The proportion of
cells exhibiting Kaiso expression was categorized as fol-
lows: 0: less than 25%; 1: 26%–50%; 2: 51%–75%; and 3:
more than 75%. The staining intensity was categorized by
relative intensity as follows: 1(weak); 2 (intermediate)
and 3 (strong). The proportion and intensity scores were
then multiplied to obtain a total score. To obtain final sta-
tistical results, score less than 1 was considered as nega-
tive, while scores of 2 or more were considered as positive.
Cases were scored nuclear positive when ≥5% of the cells
reacted with the anti-Kaiso antibody in the nucleus or in
both the cytoplasm and nucleus.
Cell culture, transfection, and antibody inhibition
The BE1 cell line was established from a human pulmo-
nary giant cell carcinoma (a gift from Dr. Jie Zheng, Med-
ical College of Beijing University, Beijing, China). Human
lung adenocarcinoma cell lines LTEP-A-2 and SPC-A-1
were obtained from the Cell Bank of Chinese Academy of
Science (Shanghai, China). The cells were cultured in
RPMI 1640 medium (GIBCO Inc., Los Angeles, CA, USA),
containing 10% fetal calf serum (GIBCO Inc., Los Ange-
les, CA, USA), 100 IU/ml penicillin (Sigma, St Louis, MO,
USA), and 100 IU/ml streptomycin (Sigma).
Three Kaiso shRNA plasmids (RHS1764-9214280,
RHS1764-9216302, and RHS1764-9692262) and a con-
trol non-silencing pSM2 shRNAmir control plasmid
(RHS1707) were purchased from the Open Biosystems
Company. The silencing sequences, inserted into the
backbone plasmid pSHAG-MAGIC2, were as follows (tar-
geted to NCBI: NM_006777):
1. TGCTGTTGACAGTGAGCG
AGGCAGTTATTAGGAGTGAAATTAGTGAAGCCACA-
GATGTAATTTCACTCCTAATAACTGCCC
TGCCTACTGCCTCGGA;
2. TGCTGTTGACAGTGAGCG
AGGTCAGAAGATCATTACTTTATAGTGAAGCCACAGAT-
GTATAAAGTAATGATCTTCTGACCC
TGCCTACTGCCTCGGA
3. TGCTGTTGACAGTGAGCG
CGCCGTTACTGTGAGAAGGTATTAGTGAAGCCACA-
GATGTAATACCTTCTCACAGTAACGGCA
TGCCTACTGCCTCGGA (Bold Codes: showing sense,
loop and antisense sequences of these shRNA plasmids).
Transfections were carried out using the Arrest-In™ Trans-
fection Reagent (Open Biosystems, USA), according to the
manufacturer's instructions. Transfected cells were har-
vested and subjected to subsequent assays after a 48 h
transfection. Considering the relative effectiveness and
stability, the second shRNA plasmid was selected by com-
paring our pilot experiments.
To further confirm the results obtained from the silencing
study, a mouse anti-human Kaiso antibody (mAb 6F,
Upstate, Lake Placid, NY) was added into the growth
medium, and a final concentration of 100 ng/ml was
maintained to the end of the study. The corresponding
control groups were treated with mouse anti-human IgG
(Beijing Zhongshan Golden Bridge Biotechnology Co.
Beijing, China) at 100 ng/ml final concentration.
Immunofluorescent staining
Immunofluorescent staining was performed as described
previously[12,15,16]. Briefly, cells grown on glass cover-
slips were fixed with ice-cold 100% methanol for 15 min-
utes at -20°C, followed by permeabilization with 0.2%
Triton X-100. Kaiso was detected using two mouse mono-
clonal antibodies (each at a concentration of 4 μg/ml; 6F
and 12H, Upstate, Lake Placid, NY and Santa Cruz Bio-
technology, Inc. respectively) and a polyclonal antibody
(C-18, Santa Cruz Biotechnology, Inc.), which were
applied overnight at 4°C. The primary antibody was fol-
lowed by incubation with a secondary antibody conju-BMC Cancer 2009, 9:178 http://www.biomedcentral.com/1471-2407/9/178
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gated to a rhodamine/fluorescein isothiocyanate (FITC)-
label, at a dilution of 1:100 (Beijing Zhongshan Golden
Bridge Biotechnology Co. Beijing, China). The nuclei were
counterstained with propidium iodide (PI, 50 μg/ml,
Sigma). The cells were examined with an Olympus IX51
fluorescent microscope (Olympus, Tokyo, Japan), and
images were recorded with a CoolPIX 5400 camera
(Nikon, Japan).
RT-PCR analysis
Total RNA was isolated using the TRIzol reagent (Invitro-
gen). cDNA was prepared using the RNA PCR Kit (AMV)
Version 3.0 (TaKaRa Bio Inc., Dalian, Liaoning, China),
according to the manufacturer's instructions. The
sequences of the primer sets, the linear amplification
range, the annealing temperatures and the numbers of the
PCR cycles are shown in Table 1. The PCR products were
electrophoresed in a 1.5% agarose gel containing 0.1 μg/
μl ethidium bromide visualized and analyzed using the
BioImaging System (UVP, Upland, CA, USA). A grayscale
intensity value was determined for each target band, and
normalized to β-actin, to provide a value for the transcrip-
tional level of each gene. Each experiment was repeated 5
times.
Immunoblotting assay
As described previously[15], frozen tissues (including
tumor and non-tumorous portion) or cells were washed
twice with ice-cold phosphate buffered saline (PBS),
homogenized on ice in 10 volumes(w/v) of lysis buffer
containing 20 mM Tris – HCl, 1 mM EDTA, 50 mM NaCl,
50 mM NaF, 1 mM Na3VO4, 1% Triton-X100 and 1 mM
PMSF using a homogenizer (Heidoph, DLA ×900). The
homogenate was centrifuged at 15000 rpm for 30 min at
4°C. The supernatant was collected and determined pro-
tein content by the BCA assay (BCA protein assay kit-
23227, Pierce Biotechnology). From each sample prepara-
tion, 80 μg of total protein was separated by 8% SDS-
PAGE and then transferred to PVDF blotting membranes.
The total protein extracts were analyzed by immunoblot-
ting with indicated antibodies following SDS-PAGE anal-
ysis. Immunoblots were performed using goat polyclonal
primary specific for Kaiso and β-actin (a housekeeping
protein used as a loading control to assure equal amounts
of protein in all lanes). After blocking non-specific bind-
ing with 5% BSA in TBS (pH 7.5) containing 0.05%
Tween-20 (TBST), primary antibodies were incubated on
the membranes for Kaiso (1:1000, C-18, Santa Cruz Bio-
technology, Inc.) and β-actin (1:200, Beijing Zhongshan
Golden Bridge Biotechnology Co. Beijing, China) over-
night at 4°C. Following three times washes in TBST, the
membranes were incubated for 2 h at 37°C with second-
ary antibodies (1:2000, ZDR-5306) labeled with horse-
radish peroxidase (all from Zhongshan Biotechnology).
Immunoreactive straps were identified using the DAB sys-
tem (DAB kit-0031, Maixin Biotechnology), as directed by
the manufacturer. The BioImaging System (UVP, Upland,
CA, USA) was used to catch up the specific bands, and the
optical density of each band was measured using Image J
software. The ratio between the optical density of interest
proteins and β-actin of the same sample was calculated as
relative content and expressed graphically.
3-(4, 5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium 
Bromide (MTT) Assay and Matrigel Invasive Assay
The shRNA-Kaiso cells, the Kaiso antibody addition cells,
and the control cells were seeded at a density of 5000
cells/well in 96-well plates. Cell proliferation was evalu-
ated each day for four days after the MTT treatment. The
absorbance, which is directly proportional to the number
of living cells in the culture, was measured at 570 nm
using a microplate reader (Model 550, Bio-Rad, Hercules,
CA, USA). A blank with dimethyl sulfoxide (DMSO)
alone was taken and subtracted from all values.
The cells' invasive abilities were examined using a 24-well
Transwell with 8-μm pore polycarbonate membrane
inserts (Corning Inc., Corning, NY, USA) according to the
manufacturer's protocol. To the upper surface of the
membranes, 100 μl Matrigel (1:4 dilution) was applied.
After solidification of the Matrigel, 100 μl of the cell sus-
pension (5 × 105 cells/ml) was added to the upper cham-
ber. Medium supplemented with 10% FBS was added to
the lower chamber as the chemoattractant. After incuba-
tion for 48 h, the filters were fixed with cold methanol,
and the non-invading cells on the upper surface were
Table 1: Primer sequences, amplification sizes and annealing temperatures used in RT-PCR.
Primer sequence(5' -> 3') Amplification range PCR setting Annealing Number of cycles
Kaiso TGCCTATTATAACAGAGTCTTT 719–966 (NM_006777.3) 50°C, 40 sec 30 cycles
AGTAGGTGTGATATTTGTTAAAG
Matrilysin TCTTTGGCCTACCTATAACTGG 241–660
(NM_002423.3)
53°C, 40 sec 35 cycles
CTAGACTGCTACCATCCGTC
β-Actin AGAGCTACGAGCTGCCTGAC 797–1096
(NM_001101.3)
55°C, 40 sec 30 cycles
AGTACTTGCGCTCAGGAGGABMC Cancer 2009, 9:178 http://www.biomedcentral.com/1471-2407/9/178
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removed by scrubbing with a cotton swab. The filters were
then subjected to hematoxylin staining. Cells that
appeared on the lower surface of the filter were counted in
five random 200× fields using an inverted microscope
(Olympus 1 × 51, Olympus America Inc., Melville, NY,
USA). The experiments were performed in triplicate and
were repeated three times independently.
Statistical analysis
The Pearson's Chi-Square test was used to analyze the rela-
tionship between cytoplasmic expression of Kaiso and
clinicopathological factors. Comparison of cytoplasmic
Kaiso expression between primary tumors and lymph
node metastases was accomplished using the McNemar's
test. All data were expressed as mean ± standard deviation
(S.D.) for in vitro experiments and were performed at least
three times. The probabilities of overall survival were cal-
culated using the Kaplan-Meier method and were com-
pared using the log-rank test. For determining factors
related to overall survival, a Cox proportional hazard
model was utilized. All statistical analyses were performed
using SPSS 13.0 for Windows (SPSS Inc., Chicago, IL,
USA). p-values less than 0.05 were considered statistically
significant.
Results
Kaiso was expressed in the cytoplasm of lung cancer cells 
and is associated with the malignancy of NSCLC
Kaiso was weakly expressed in the ciliated epithelial cells
of bronchus from all 20 normal pulmonary tissues and
primarily localized on the apiculus of these cells (Figure
1A) and several glands (Figure 1B). According to our eval-
uation criteria, they were judged as negative expression.
Positively staining tumor cells primarily showed cytoplas-
mic labeling of Kaiso (Figure 1C, D, E, and 1F). Nuclear
staining was seen in occasional tumor cells but only with
a 5.10% (15/294) positive expression rate (Figure 1G).
This pattern of staining was not associated with any clin-
icopathological features of NSCLC (data not shown). The
specificity of the Kaiso subcellular staining was confirmed
with another polyclonal antibody (C-18).
The positive cytoplasmic expression of Kaiso in NSCLC
was 63.61% (187/294), which is significantly higher than
that in normal bronchial epithelium (p < 0.001). The rela-
tionships between the cytoplasmic expression of Kaiso
and the different clinicopathological factors are shown in
Table 2. The positive cytoplasmic expression of Kaiso was
higher in stages III+IV NSCLC than in stages I+II (p  =
0.019). In 163 cases with lymph node metastases, 116
(71.2%) showed cytoplasmic expression, and 47 (28.8%)
had no cytoplasmic expression. In 131 samples without
lymph node metastasis, 71 (54.2%) showed cytoplasmic
expression, and 60 (45.8%) had no cytoplasmic expres-
sion. There was a significant correlation between cytoplas-
mic Kaiso expression and lymph node metastasis (p  =
0.003). In addition, there were no significant correlations
between cytoplasmic Kaiso expression and gender, age,
differentiation, or histology.
The expression of Kaiso in the 50 cases for which paired
data were available is summarized in Table 3. The positive
scoring of cytoplasmic Kaiso was 78.0% (39/50) in the
primary sites and 90.0% (45/50) in the lymph node
metastases. Lymph node metastases showed an increased
expression rate in cytoplasmic Kaiso, compared to the pri-
mary tumors (p = 0.001).
Western blotting was used to evaluate Kaiso expression in
20 NSCLC and paired non-tumorous lung tissues distant
from the primary tumor of the same case. The increased
Kaiso expression was found in 18 NSCLC samples in com-
parison with the non-tumorous counterparts. The western
blotting of four samples is shown in Figure 2A, and the
optical density of the tumorous (T) and non-tumorous
(N) tissues of the same patient was measured and
expressed graphically (Figure 2B). Kaiso expression was
significant higher in tumorous tissues (t = 10.610, n = 20,
p = 0.000).
The overall Kaplan-Meier survival curves for cytoplasmic
Kaiso expression are shown in Figure 3. The total lung
cancer-related five-year survival rate was 34.1%, while
22.22% in patients positive for cytoplasmic Kaiso and
64.00% in patients negative for cytoplasmic Kaiso. Uni-
variate analysis revealed cytoplasmic expression of Kaiso
to be linked to poor overall survival. Survial rate of
patients with positive cytoplasmic Kaiso expression was
significantly lower than those with cytoplasmic Kaiso-
negative tumors (p = 0.002, Figure 3).
To further evaluate the cytoplasmic expression of Kaiso as
prognostic factor, a multivariate Cox regression analysis
was carried out. As shown in Table 4, in an analysis of 88
patients, lymph node metastasis (p = 0.001) and tumor
stage (p = 0.047) were independent prognostic factors.
Additionally, cytoplasmic Kaiso status may be an inde-
pendent prognostic factor for the p-value (p = 0.054).
shRNA-Kaiso effectively ablated nuclear Kaiso expression 
of in vitro cultured lung cancer cells
In contrast to the cytoplasmic localization pattern of
Kaiso in tissues, all three lung cancer cell lines showed a
primarily nuclear localization of Kaiso. Following trans-
fection with shRNA-Kaiso, the nuclear Kaiso staining was
accordingly decreased, even vanishing in several trans-
fected lung cancer cells, which was not observed in the
control cells (Figure 4A, B, and 4C). In addition, RT-PCR
and immunoblotting results demonstrated that Kaiso
mRNA and protein levels were significantly down-regu-BMC Cancer 2009, 9:178 http://www.biomedcentral.com/1471-2407/9/178
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Immunohistochemical analysis of Kaiso expression Figure 1
Immunohistochemical analysis of Kaiso expression. Kaiso was expressed in the cytoplasm of normal adult bronchial 
epithelial cells (A) and glands (B). The expression of Kaiso was increased in metastases of lung adenocarcinomas (D) and squa-
mous cell carcinomas (F), compared to the matched primary tumor (C, D). Nuclear Kaiso staining was observed occasionally 
primary tumors (G, black arrow), with cytoplasmic staining of tumor cells in paired metastases. A magnification scale bar of 20 
μm is shown.BMC Cancer 2009, 9:178 http://www.biomedcentral.com/1471-2407/9/178
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lated in the shRNA-Kaiso cells, compared with the control
group (p < 0.05 in all lung cancer cell lines).
Down-regulating nuclear Kaiso increases matrilysin 
transcription and enhances the proliferative and invasive 
abilities of lung cancer cells
Since Kaiso primarily localized to the nucleus in vitro, it
was conceivable to explore the biological role of nuclear
Kaiso in lung cancers using in vitro cultured cells. The MTT
assay results demonstrated that after down-regulating
nuclear Kaiso by transfecting shRNA-Kaiso, the levels of
proliferation were significantly higher in the shRNA-Kaiso
group cells, compared to the control cells [p > 0.05(day 1);
p < 0.05(day 2–3), n = 3] (Figure 5B). For the Kaiso anti-
body addition groups, the growth rates were markedly dif-
ferent from the control cells at all three days. Meanwhile,
the shRNA-Kaiso cells and the Kaiso antibody-treated cells
showed increased invasion onto the lower surfaces of the
Transwell filters, compared to control cells (p < 0.01, Fig-
ure 5A).
To further confirm whether the enhancement of prolifer-
ative and invasive abilities contributes to Kaiso down-reg-
ulation in the nucleus, matrilysin  mRNA levels were
detected by RT-PCR. The results demonstrated that matri-
lysin mRNA increased significantly in both shRNA-Kaiso
and Kaiso antibody-treated cells, compared with controls
(p < 0.01, Figure 6).
Discussion
With immunohistochemical analysis of small sample
sizes, Kaiso has been shown to be expressed in human
Table 2: Relationship between cytoplasmic Kaiso expression and clinical/histological features in 294 patients with NSCLCs
Variables All patients Cytoplasmic Kaiso expression p*
Negative Positive
Total 294 107 187
Age(y)
≤ 55 125 51 74 0.177
>55 169 56 113
Gender
Male 165 59 106 0.797
Female 129 48 81
Stage
I/II 152 65 87 0.019
III/IV 142 42 100
Histology
Squamous cell Carcinoma 133 41 92 0.343
Adenocarcinoma 146 60 86
Large cell Carcinoma 12 5 7
Adenosquamous Carcinoma 3 1 2
Grade
Well 78 33 45 0.296
Moderate 100 36 64
Poor 116 38 78
Lymph node metastasis
Yes 163 47 116 0.003
No 131 60 71
*p values were obtained with the X2 test (two-sided).
**Well, moderate, versus poor.
Table 3: Correlation between cytoplasmic Kaiso expressions in matched primary tumors and autologous lymph node metastases of 
NSCLCs
Cytoplasmic Kaiso in the Primary Growth Total p
Positive Negative
Cytoplasmic Kaiso in
Lymph node metastases
Positive 38 7 45 0.001
Negative 14 5
Total 39 11BMC Cancer 2009, 9:178 http://www.biomedcentral.com/1471-2407/9/178
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tumors, such as breast cancers and prostate cancers, with
varying expression in one report[8]. Due to lack of infor-
mation regarding to Kaiso expression in tumors, no Kaiso
positive criterion has been detailed by researchers. Thus, a
criterion still needed to be specified in the current study.
Based on the basic expression profile of Kaiso in NSCLC
and in consulting with general criterion widely applied in
immunohistochemical studies, we considered expression
of cytoplasmic Kaiso to be positive when scores of 2 or
more, because the distribution ratio of stained cells
showed bipolarity using this method. We also found that
no significant difference between cytoplasmic Kaiso local-
ization and clinicopathological features could be eluci-
dated when other positive criterions were applied.
The transcriptional repressor Kaiso belongs to the BTB/
POZ (Broad-Complex, Tramtrack and Bric-a-brac/Pox
virus, and Zinc finger) family[1,2], which is abbreviated as
POZ-ZF. Many members of the POZ-ZF family have roles
in the development of cancer. For example, APM-1 inhib-
its the growth of cervical carcinoma[17], and the human
BCL-6 and promyelocytic leukemia zinc finger proteins
are causally involved in non-Hodgkin's lymphoma and
acute promyelocytic leukemia, respectively[18,19]. In
addition, Pokemon was proven to be a type of proto-
oncogene[20], whereas the BTB/POZ protein HIC1 is can-
didate tumor suppressor in a variety of human tumors
[21-23]. However, the relationship between Kaiso and
cancer still needs to be clarified. Some data clearly indi-
cate a tumor-suppressor activity[3,24], while the fact that
a Kaiso knockout was detrimental to tumor growth and
survival in an animal model suggests that Kaiso facilitates
tumorigenesis[6]. The latter point is consistent with
results obtained from a recent study where Kaiso deple-
tion sensitized colon cancer cells to cell cycle arrest and
chemotherapy.
There is little documentation regarding to the immuno-
histochemical expression of Kaiso in lung cancer. Only
one report examines Kaiso expression in lung cancer tis-
sues, and the author reported no Kaiso expression in two
lung squamous cell carcinomas[8]. Since there is little cur-
rent knowledge about Kaiso expression in lung cancer, its
expression profile and relationship to clinical characteris-
tics still needed to be clarified. In the present study, we
examined the expression of Kaiso in 294 cases non-small
cell lung cancers (NSCLC) and analyzed the correlation
between expression of Kaiso and clinicopathological fac-
tors. Meanwhile, Kaiso expression was assessed in 50 cases
of lymph node metastases to investigate differences
Kaiso expression in NSCLC by Western blotting Figure 2
Kaiso expression in NSCLC by Western blotting. (A) 
Representative results of Kaiso protein expression in 
matched tumourous (T) and surrounding non-tumorous (N) 
tissues from 8 of 20 NSCLC patients. Lane T: tumor tissue; 
Lane S: Surrounding normal lung tissue. Samples: case 4; case 
6; case 8; case 18. Band intensities indicate significant Kaiso 
up-regulation in tumorous in comparison with the non-
tumorous tissue of the same patient. β-actin was used as a 
loading control to assure equal amounts of protein in all 
lines. (B) The ratio between the optical density of Kaiso and 
β-actin of the same patient was calculated and expressed 
graphically. The significant difference of Kaiso expression 
between tumorous (T) and non-tumorous (N) tissues was 
analyzed statistically. Kaiso immunoreactivity is greater in 
neoplastic tissues (p = 0.000). Data were expressed as mean 
± standard deviation (S.D.). Columns, mean (n = 20); error 
bars, S.D.
Kaplan-Meier analysis showing overall survival among  NSCLC patients, based on their positive and negative Kaiso  expression Figure 3
Kaplan-Meier analysis showing overall survival 
among NSCLC patients, based on their positive and 
negative Kaiso expression. Positive cytoplasmic expres-
sion of Kaiso was significantly correlated with poor prognosis 
(p = 0.002).BMC Cancer 2009, 9:178 http://www.biomedcentral.com/1471-2407/9/178
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between primary lung cancer and paired lymph node
metastases. Our study demonstrated that 63.61% of 294
lung cancer samples contained cytoplasmic Kaiso expres-
sion, which is a significant increase compared to normal
bronchial epithelial cells (regarded as negative expres-
sion). This data implied an oncogenic role for Kaiso.
Besides, the 294 cases with primary lung cancer showed
that, cytoplasmic Kaiso expression in lung cancer tissue of
patients with TNM stages III+IV was significantly higher
than that in TNM stages I+II (p = 0.019). Moreover, cyto-
plasmic expression (71.2%) of Kaiso in the lung cancer
samples from patients with lymph node metastases was
significantly higher than that (54.2%) in samples from
patients without lymph node metastases, suggesting that
cytoplasmic Kaiso expression in primary cells was closely
associated with tumor lymph node metastases (p  =
0.003). In 50 paired cases, we also observed that lymph
node metastases had increased (90.0%) cytoplasmic
expression of Kaiso, compared to the primary tumors
(78.0%) in fifty paired lung cancer specimens. In order to
define the effect of cytoplasmic Kaiso on prognosis of the
patients with lung cancer, eighty-eight NSCLC tissues with
complete follow-up records were analyzed with immuno-
histochemistry. Prognostic analysis were performed on
the clinical information by combining follow-up data,
and the results indicate that the postoperative survival
period of the group with positive cytoplasmic Kaiso
expression was notably shorter than that of the negative
group. Specifically, these results suggested that cytoplas-
mic Kaiso expression was a harmful factor affecting prog-
nosis and further indicated that cytoplasmic Kaiso
correlated with malignant tumor behavior. Cox model
multivariate analysis showed that cytoplasmic Kaiso may
be an independent factor affecting prognosis, with a p-
value of 0.054. It seems important to collect more patient
follow-up records to clarify this correlation between Kaiso
expression and a patient's clinical response. Kaiso may
exert an anti-oncogenic function in the cytoplasm of lung
cancer cells. Obviously, this suggestion seems antagonis-
tic of its role as a transcriptional repressor, but Kaiso may
function in different biological roles in the cytoplasm and
the nucleus. While we are still unsure of how Kaiso exerts
its function in the cytoplasm, we believe that Kaiso plays
a biological role in the cytoplasm, and this role may differ
from that in the nucleus.
In lung cancer tissues, we found Kaiso to be primarily
localized in the cytoplasm rather than the nucleus. In fact,
the positive nuclear scoring of Kaiso was extremely low.
Even when we defined nuclear staining of 5% of the cells
in a sample as positive, only 15 cases were included. Our
statistical analysis showed that nuclear expression of
Kaiso did not correlate with various pathological factors.
Considering the influence of unexpected tumor microen-
vironment[8], which may promote Kaiso to translocate
from nucleus to cytoplasm, we supposed it was hard to
clarify the nuclear role of Kaiso in lung cancer tissues.
Consistent with previous study[8], we also found Kaiso
principally localized in the nucleus when cells cultured in
vitro. The subcellular localization difference of Kaiso
between in vitro and in vivo could be explained by the
tumor microenvironment. We also have data implying
that other factors, such as the cell cycle and the influence
of p120ctn, influence the subcellular localization of Kaiso
(data not shown). We did not plan to extend this theme
further in present study, although we were interested in
whether Kaiso exerted its varying functions in the cyto-
plasm or the nucleus. Thus, we cultured three kinds of
lung cancer cells (BE1, LTEP-A-2, and SPC-A-1)in vitro and
observed where Kaiso is localized. Indirect immunofluo-
rescence demonstrated that Kaiso is localized to the
nucleus in these three lung cancer cell lines. We per-
formed the shRNA technique to down-regulate nuclear
localized Kaiso, and we utilized a specific Kaiso antibody
as a control. The results demonstrated that both the
shRNA-Kaiso and the specific Kaiso antibody addition
were able to enhance the proliferative and invasive abili-
ties of lung cancer cell lines.
In order to determine whether the enhancement of prolif-
erative and invasive abilities contributed to the down-reg-
ulation of nuclear Kaiso, we analyzed mRNA expression
of the matrilysin gene, which is directly repressed by Kaiso.
This repression is due to the matrilysin promoter, which
contains two conserved copies of the Kaiso binding
sequence (KBS). At present, this gene has been proven to
be regulated by Kaiso[3,25]. Addition of specific Kaiso
antibodies also relieved the Kaiso-mediated repression of
matrilysin. These studies demonstrated that the enhance-
ment of proliferative and invasive abilities was consistent
with down-regulation of Kaiso in nucleus.
It should be noted that differences in the up-regulation of
matrilysin transcription and in the proliferative and inva-
sive abilities existed between the Kaiso antibody addition
Table 4: Multivariate Cox proportional hazard analysis for overall survival of 88 patients with NSCLCs
Factors β S.E. P value Exp (β) 95% CI for Exp (β)
TNM stage 0.487 0.245 0.047 1.627 1.007–2.632
Lymph node metastasis 1.726 0.507 0.001 5.620 2.079–15.196
Cytoplasmic Kaiso expression 0.718 0.372 0.054 2.051 0.988–4.256BMC Cancer 2009, 9:178 http://www.biomedcentral.com/1471-2407/9/178
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shRNA-Kaiso efficiently down-regulates nuclear Kaiso expression in three lung cancer cell lines Figure 4
shRNA-Kaiso efficiently down-regulates nuclear Kaiso expression in three lung cancer cell lines. shRNA-Kaiso 
efficiently down-regulated nuclear Kaiso expression in three lung cancer cell lines. Specifically, nuclear staining of Kaiso was 
detected by immunofluorescence in BE1, LTEP-A-2, and SPC-A-1 cells (top rows in A, B, and C). After transfected with 
shRNA-Kaiso, BE1, LTEP-A-2, and SPC-A-1 cells showed significantly reduced green/yellow signals in the nucleus, while there 
was no signal detected in several transfected cells (bottom rows in A, B, and C), compared with controls (middle rows in A, B, 
and C). Results from RT-PCR and immunoblotting assays were shown in D and E. Little bands or dots can be detected after 
transfection with shRNA-Kaiso, which demonstrated that levels of Kaiso mRNA and protein were down-regulated significantly 
(p < 0.05). β-actin served as an internal control. Data were expressed as mean ± standard deviation (S.D.). Columns, mean (n 
= 3); error bars, S.D.BMC Cancer 2009, 9:178 http://www.biomedcentral.com/1471-2407/9/178
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Down-regulated nuclear Kaiso increases matrilysin transcription and enhances the proliferative and invasive ability of lung can- cer cells Figure 5
Down-regulated nuclear Kaiso increases matrilysin transcription and enhances the proliferative and invasive 
ability of lung cancer cells. A. Invasion assays of BE1, LETP-A-2, and SPC-A-1 cells, which were transfected with shRNA-
Kaiso or treated with the addition of a Kaiso antibody. Forty-eight hours after plating on Matrigel, the number of cells invading 
the lower surface of the filter was far greater in the controls. Data were expressed as mean ± standard deviation (S.D.). Col-
umns, mean (n = 3); error bars, S.D. B. Cell proliferation was determined using the MTT assay. The absorbance at 570 nm rep-
resents cell viability at each time point and is a measure of cell proliferation. The growth rates were not markedly different 
during the first day after transfection, but in each of the latter two days, the growth rate was significantly higher in shRNA-
Kaiso groups, compared to controls. For the Kaiso antibody addition groups, significant differences were observed at all three 
days. Points, mean (n = 3); Bar, S.D. *, p < 0.001.BMC Cancer 2009, 9:178 http://www.biomedcentral.com/1471-2407/9/178
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group and the shRNA-Kaiso group. These results could be
explained by the fact that different experimental treat-
ments were used on the cells for each experiment; cells
transfected with shRNA Kaiso plasmids suffered from the
effectiveness of transfection, while treating with a Kaiso
antibody could exert more extensive effects throughout
the culture.
Conclusion
Above all, in lung cancer tissues, we found that Kaiso is
principally expressed in the cytoplasm, which positively
correlated with TNM stage, lymph node metastases, and
potentially with unfavorable prognosis of patients. How-
ever, whether Kaiso can be used as an independent prog-
nostic factor still needs further clarification (p = 0.054,
Cox multivariate analysis). As for several in vitro cultured
lung cancer cell lines, Kaiso localized primarily in the
nucleus. Performing both shRNA-Kaiso and using addi-
tion of Kaiso-specific antibodies, we were able to increase
the expression of matrilysin, which is repressed by Kaiso,
and promote proliferative and invasive abilities of the
cells. Although our research is still preliminary, it has
already demonstrated unique biological functions for the
different localization of Kaiso in the cytoplasm and the
nucleus. We also noticed that although Kaiso is basically
localized to the nucleus in cultured cells, cells showing
cytoplasmic or nuclear/cytoplasmic co-expression existed.
Thus, it is worthwhile in the future to construct plasmids
that enhance the cytoplasmic-specific and nuclear-specific
localization of Kaiso in order to clarify the biological roles
of cytoplasmic and nuclear Kaiso. These types of studies
will also help elucidate the specific mechanisms that will
further reveal the inner relationship between cytoplasmic
Kaiso expression and lymph node metastasis, as well as
poor prognosis.
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Down-regulated nuclear Kaiso increases matrilysin transcription in three kinds of lung cancer cell lines Figure 6
Down-regulated nuclear Kaiso increases matrilysin transcription in three kinds of lung cancer cell lines. (A) The 
electrophoresis images of matrilysin mRNA in BE1, BE1+empty, BE1+shRNA-Kaiso, BE1+IgG, and BE1+Kaiso antibody cells 
after RT-PCR. β-actin served as an internal control. The relative expression of matrilysin mRNA was significantly enhanced in 
BE1+shRNA-Kaiso and BE1+Kaiso antibody cells. Columns, mean (n = 3); bar, SD. *, p < 0.01. (B) The electrophoresis images 
of matrilysin mRNA in LTEP-A-2, LTEP-A-2+empty, LTEP-A-2+shRNA-Kaiso, LTEP-A-2+IgG, and LTEP-A-2+Kaiso antibody 
cells after RT-PCR. β-actin served as an internal control. The relative expression of matrilysin mRNA was significantly enhanced 
in LTEP-A-2+shRNA-Kaiso and LTEP-A-2+Kaiso antibody cells. Columns, mean (n = 3); bar, SD. *, p < 0.01. (C) The electro-
phoresis images of matrilysin mRNA in SPC-A-1, SPC-A-1+empty, SPC-A-1+shRNA-Kaiso, SPC-A-1+IgG, and SPC-A-1+Kaiso 
antibody cells after RT-PCR. β-actin served as an internal control. The relative expression of matrilysin mRNA was significantly 
enhanced in SPC-A-1+shRNA-Kaiso and SPC-A-1+Kaiso antibody cells. Columns, mean (n = 3); bar, SD. *, p < 0.01.BMC Cancer 2009, 9:178 http://www.biomedcentral.com/1471-2407/9/178
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